News
Steep cost of surviving childhood HL: Epigenetic aging
- Author:
- Neil Osterweil
New research found accelerated epigenetic aging in most adults who survived pediatric Hodgkin lymphoma.
News
Alloantibody registry would save lives, money
- Author:
- Neil Osterweil
New research supports establishing a national exchange of alloantibody data, to save lives and cut costs in transfusion medicine.
News
![](https://qa00.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
Gene signature may spare some breast cancer patients from radiation
- Author:
- Neil Osterweil
The POLAR 16-gene mRNA signature accurately identified patients who were unlikely to benefit from radiotherapy after breast-conserving surgery.
News
‘Exciting’ responsiveness to talquetamab for r/r MM
- Author:
- Neil Osterweil
The novel antibody talquetamab may buy time for patients with multiple myeloma (MM) for whom few other options remain.
News
Pricey gene therapy looks cost-effective for SCD
- Author:
- Neil Osterweil
Researchers calculated that a costly new treatment being developed for sickle cell disease (SCD) promises to be worth the price.
News
A bold national plan to eliminate HCV by 2050
- Author:
- Neil Osterweil
“We don’t get to use the ‘eliminate’ word all that often with a disease that’s taking thousands or tens of thousands – or worldwide, hundreds of...
News
![](https://qa00.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
High response rates with T-DXd in early HER2-low breast cancer
- Author:
- Neil Osterweil
Nearly 70% of patients with hormone receptor-positive breast cancers with low levels of HER2 had pathological response to the antibody-drug...
News
‘Clear answer’: ALL study defies conventional wisdom
- Author:
- Neil Osterweil
Research on pediatric blood cancers found that high-dose methotrexate does not help cut the risk for central nervous system relapse.
News
‘Astonishing’ results: Skip salvage chemo, proceed to HSCT
- Author:
- Neil Osterweil
New research on treating acute myeloid leukemia suggested that some patients may safely go straight to stem cell transplantation.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Oliveira_Mafalda_SPAIN_web_0.jpg)
Oral SERD camizestrant prolongs PFS vs. fulvestrant in breast cancer
- Author:
- Neil Osterweil
The investigational selective estrogen receptor degrader showed efficacy in advanced ER+/HER2– breast cancers, including patients with ESR1...
News
![](https://qa00.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
Chemotherapy meets its match against aggressive ER+/HER2– breast cancers
- Author:
- Neil Osterweil
Ribociclib plus endocrine therapy resulted in high response rates and double progression-free survival over combo chemotherapy.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Oktay_Maja_NY_web_0.png)
Potential cause of worse outcomes among Black breast cancer patients found
- Author:
- Neil Osterweil
Tumor microenvironment of metastasis doorways predicted worse outcomes in Black women with residual ER+/HER2– cancer after neoadjuvant...
News
ASH 2022: New clinical data challenge long-held assumptions
- Author:
- Neil Osterweil
Fresh research to be unveiled at the 2022 American Society of Hematology conference seems to overturn conventional wisdom across a range of issues...
News
Poor NAFLD outcomes with increased VCTE-measured liver stiffness
- Author:
- Neil Osterweil
The findings show that “progression to LSM-defined cirrhosis by VCTE is strongly associated with poor clinical outcomes.”
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Bass_Anne_NY_web.jpg)
New ACR vaccination guideline: Take your best shot
- Author:
- Neil Osterweil
Vaccinate patients with rheumatic and musculoskeletal disease against flu and other vaccine-preventable disease whenever possible, experts say.